Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AKTX logo AKTX
Upturn stock ratingUpturn stock rating
AKTX logo

Akari Therapeutics PLC (AKTX)

Upturn stock ratingUpturn stock rating
$1.24
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: AKTX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit 4.36%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 30.35M USD
Price to earnings Ratio -
1Y Target Price 80
Price to earnings Ratio -
1Y Target Price 80
Volume (30-day avg) 50950
Beta 0.95
52 Weeks Range 0.90 - 4.40
Updated Date 02/9/2025
52 Weeks Range 0.90 - 4.40
Updated Date 02/9/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.58

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -172.83%
Return on Equity (TTM) -1281.43%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 31581877
Price to Sales(TTM) -
Enterprise Value 31581877
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.06
Shares Outstanding 20645200
Shares Floating 10536966175
Shares Outstanding 20645200
Shares Floating 10536966175
Percent Insiders 11.91
Percent Institutions 0.51

AI Summary

Akari Therapeutics PLC (NASDAQ: AKTX): A Comprehensive Overview

Company Profile:

History and Background:

Akari Therapeutics PLC (AKTX) is a clinical-stage biopharmaceutical company that researches, develops, and commercializes innovative therapeutics for the treatment and prevention of various diseases. Founded in 2009, the company is headquartered in London, United Kingdom, and has facilities in the United States and Europe.

Business Areas:

Akari focuses on two key business areas:

  • Therapeutics: Development of oral small molecule therapies for areas with significant unmet medical needs, including the treatment of addiction, pain management, and chronic kidney disease
  • Vaccines: Development of novel, non-replicating virus-like particle (VLP) vaccine technology platform for infectious diseases, including a universal influenza vaccine and a vaccine for COVID-19

Leadership Team and Corporate Structure:

Akari's leadership team comprises experienced professionals with expertise in drug development, commercialization, and finance. The company operates a flat organizational structure, which facilitates quick decision-making and an agile approach to development.

Top Products and Market Share:

Products:

  • Fenfluramine: A repurposed serotonin releaser for the treatment of Prader-Willi syndrome (PWS)
  • Oligonucleotide-based therapies: For the treatment of Duchenne muscular dystrophy (DMD)
  • VLP-based Vaccines: For various infectious diseases

Market Share:

  • Fenfluramine: Currently holds orphan drug designation for PWS, giving it a significant market share in this niche area.
  • Oligonucleotide-based therapies: The market is dominated by established players like Sarepta and Exonics. AKTX's therapies are in early development and have not yet secured market share.
  • VLP-based Vaccines: The market is highly competitive, with major players like Pfizer and Sanofi. AKTX's vaccines are still in preclinical stages and have not yet entered the market.

Total Addressable Market:

  • PWS: Estimated global market size of $300-500 million
  • DMD: Estimated global market size of $3-5 billion
  • Influenza Vaccines: Estimated global market size of $5-7 billion
  • COVID-19 Vaccines: Estimated global market size of $20-30 billion

Financial Performance:

Recent Financials:

  • Revenue: Minimal as no commercialized products exist.
  • Net Income: Loss of $45 million in 2022 due to ongoing research and development expenses.
  • Profit Margins: Negative, reflecting the company's early-stage development.
  • Earnings per Share (EPS): Loss of $1.24 per share in 2022.

Financials Comparison:

Financial performance is marked by growth in R&D expenses as the company advances its pipeline. Revenue remains limited to licensing agreements.

Cash Flow and Balance Sheet:

The company relies heavily on external funding through partnerships and offerings to sustain operations. The cash burn rate is high due to ongoing clinical trials.

Dividends and Shareholder Returns:

Dividend History:

Akari does not currently pay dividends due to its focus on growth and development.

Shareholder Returns:

Shareholder returns have been negative due to the company's early stage and lack of commercialized products.

Growth Trajectory:

Historical Growth:

Revenue and earnings are expected to remain non-existent until the commercialization of Fenfluramine for PWS.

Future Growth Projections:

Future growth is contingent upon the successful development and commercialization of its pipeline, particularly Fenfluramine and its oligonucleotide therapies.

Recent Product Launches and Growth Initiatives:

The company anticipates the launch of Fenfluramine for PWS in 2024, which is expected to contribute significantly to revenue and earnings growth.

Market Dynamics:

Industry Trends:

The pharmaceutical industry is characterized by high R&D costs, stringent regulations, and intense competition. However, it also presents opportunities for innovative companies with breakthrough therapies.

Competitive Landscape:

AKTX faces competition from established players in the therapeutic and vaccine markets. Its success will depend on its ability to differentiate its products and gain market share.

Competitors:

  • PWS: Zogenix (ZGNX)
  • DMD: Sarepta Therapeutics (SRPT), Exonics Therapeutics (XONE)
  • Vaccines: Pfizer (PFE), Sanofi (SNY)

Key Challenges and Opportunities:

Challenges:

  • High R&D costs
  • Stringent regulatory approval process
  • Intense competition from established players
  • Dependence on external funding

Opportunities:

  • Large addressable markets
  • Unmet medical needs in targeted areas
  • Potential for significant market share with breakthrough therapies
  • Strategic partnerships and collaborations

Recent Acquisitions:

Akari has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Rating: 4 out of 10

Justification:

AKTX is an early-stage company with a promising pipeline and significant market opportunities. However, the lack of commercialized products, negative financials, and intense competition present challenges. The company's success hinges on the successful development and commercialization of its pipeline, particularly Fenfluramine for PWS.

Sources and Disclaimers:

Sources:

Disclaimer:

This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Additional Notes:

  • This analysis is based on publicly available information as of November 2023.
  • Data and projections may change as the company progresses and market conditions evolve.

About Akari Therapeutics PLC

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2015-09-21
Interim President, CEO & Director Dr. Samir Rashmikant Patel M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​